SOBI_logo_PNG_0.png
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
24 mai 2024 15h16 HE | Sobi, Inc.
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
SOBI_logo_PNG_0.png
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
04 avr. 2023 07h00 HE | Sobi, Inc.
WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic...